Glaukos Corporation $GKOS Shares Sold by Great Lakes Advisors LLC

by · The Cerbat Gem

Great Lakes Advisors LLC reduced its stake in shares of Glaukos Corporation (NYSE:GKOS – Free Report) by 6.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 106,200 shares of the medical instruments supplier’s stock after selling 7,101 shares during the quarter. Great Lakes Advisors LLC’s holdings in Glaukos were worth $10,452,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Jones Financial Companies Lllp lifted its stake in shares of Glaukos by 1,405.9% during the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after buying an additional 2,390 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Glaukos during the first quarter worth $307,000. Rockport Wealth LLC acquired a new stake in shares of Glaukos during the first quarter worth $1,132,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Glaukos by 4.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,593 shares of the medical instruments supplier’s stock worth $3,109,000 after buying an additional 1,244 shares during the period. Finally, Eventide Asset Management LLC acquired a new stake in shares of Glaukos during the first quarter worth $28,636,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Down 2.2%

GKOS opened at $91.83 on Tuesday. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The company has a fifty day moving average of $94.77 and a two-hundred day moving average of $96.44. The stock has a market capitalization of $5.27 billion, a price-to-earnings ratio of -55.66 and a beta of 0.77.

Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million during the quarter, compared to analysts’ expectations of $115.49 million. During the same quarter in the previous year, the company earned ($0.52) earnings per share. The firm’s revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Mizuho set a $130.00 target price on shares of Glaukos in a research report on Thursday, July 31st. UBS Group boosted their target price on shares of Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. BTIG Research restated a “buy” rating on shares of Glaukos in a research report on Monday, July 14th. Finally, Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and a consensus price target of $127.42.

Get Our Latest Report on Glaukos

About Glaukos

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

See Also

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).